Gilead Sciences Acquires Forty Seven for $4.9 Billion

Gilead Sciences Acquires Immunomedics

September 13, 2020

Biotechnology

Gilead Sciences agreed to acquire Immunomedics for $88.00 per share in an all-cash transaction valuing Immunomedics at approximately $21 billion. The acquisition gives Gilead global rights (outside certain Asian territories) to Trodelvy, an FDA‑approved antibody‑drug conjugate for metastatic triple‑negative breast cancer, and accelerates Gilead’s expansion into oncology.

Gilead Sciences Acquires MiroBio

September 20, 2022

Biotechnology

Gilead Sciences completed the acquisition of U.K.-based biotechnology company MiroBio for approximately $405 million in cash. The deal gives Gilead MiroBio's discovery platform and portfolio of immune inhibitory receptor agonists, including lead investigational antibody MB272, which is in Phase 1 clinical trials.

GlaxoSmithKline Acquires Sierra Oncology for $1.9bn

April 13, 2022

Biotechnology

GlaxoSmithKline plc (GSK) has agreed to acquire late-stage biopharmaceutical company Sierra Oncology for $55 per share in cash, representing an approximate equity value of $1.9 billion. The acquisition, expected to close in Q3 2022 subject to customary approvals, brings momelotinib — a late-stage JAK/ACVR1 inhibitor with demonstrated benefit on symptoms, splenic response and anaemia in myelofibrosis — into GSK's haematology portfolio to strengthen its specialty medicines capability and global commercial reach.

Gilead Sciences Acquires CymaBay Therapeutics for $4.3 Billion

February 12, 2024

Biotechnology

Gilead Sciences has completed the acquisition of CymaBay Therapeutics for approximately $4.3 billion, paying $32.50 per share in cash. The deal adds CymaBay's investigational PPARδ agonist seladelpar for primary biliary cholangitis (PBC) to Gilead's liver-disease portfolio and is expected to accelerate development and potential commercialization of the therapy.

AbbVie to Acquire ImmunoGen for $10.1 Billion

November 30, 2023

Biotechnology

AbbVie has entered into a definitive agreement to acquire ImmunoGen for $31.26 per share in cash, valuing the company at approximately $10.1 billion. The deal gives AbbVie commercial rights to ELAHERE (mirvetuximab soravtansine-gynx) and ImmunoGen's ADC pipeline, expanding AbbVie's oncology capabilities; the transaction is expected to close in mid-2024 subject to shareholder and regulatory approvals.

Merck Acquires OncoImmune

November 23, 2020

Biotechnology

Merck will acquire all outstanding shares of clinical-stage biopharmaceutical OncoImmune for $425 million upfront in cash, with additional sales-based and regulatory milestone payments possible. The deal centers on accelerating development of OncoImmune’s CD24Fc for severe and critical COVID-19; non-CD24Fc assets will be spun out into a new company in which Merck will invest $50 million for a minority stake.